The medical device company has been trading sideways for a long time and is likely to continue in the manner.
If prices continue higher they are likely to encounter resistance above $120.
The technical signs indicate the stage may be set for new highs in the maker of medical devices.
However, more consolidation may be needed before the uptrend resumes.
The terror that the futures struck, rightly or wrongly, has disappeared.
Breadth has improved quite a bit, but it is a challenge to find new inventory.
Animal health and oncology deal activity is heating up in 2017.
The Mars-VCA deal is yet another sign that pet health is a robust business.
This small-cap has 2 intriguing medicinal compounds under development.
At least, that's the case when it comes to a technical trade.


News Breaks

Powered by


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.